Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

• Kamrine E. Poels,
• Adam J. Schoenfeld,
• Alex Makhnin,
• Yosef Tobi,
• Yuli Wang,
• Heidie Frisco-Cabanos,
• Shaon Chakrabarti,
• Manli Shi,
• Chelsi Napoli,
• Thomas O. McDonald,
• Weiwei Tan,
• Aaron Hata,
• Scott L. Weinrich,
• Helena A. Yu,
• Franziska Michor

Affiliations

Kamrine E. Poels

Department of Biostatistics, Harvard T.H. Chan School of Public Health

Adam J. Schoenfeld

Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College

Alex Makhnin

Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College

Yosef Tobi

Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College

Yuli Wang

Oncology Research and Development, Pfizer Inc

Heidie Frisco-Cabanos

Massachusetts General Hospital Cancer Center

Shaon Chakrabarti

Department of Biostatistics, Harvard T.H. Chan School of Public Health

Manli Shi

Oncology Research and Development, Pfizer Inc

Chelsi Napoli

Massachusetts General Hospital Cancer Center

Thomas O. McDonald

Department of Biostatistics, Harvard T.H. Chan School of Public Health

Weiwei Tan

Clinical Pharmacology Oncology, Global Product Development, Pfizer Inc

Aaron Hata

Massachusetts General Hospital Cancer Center

Scott L. Weinrich

Oncology Research and Development, Pfizer Inc

Helena A. Yu

Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College

Franziska Michor

Department of Biostatistics, Harvard T.H. Chan School of Public Health